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Objectives. We aimed to assess in vivo the long-term effects of percutaneous transluminal angioplasty (PTA) and endo-
vascular brachytherapy (EVBT) on vessel wall by serial MRI.
Methods. Twenty patients with symptomatic stenosis of the femoropopliteal artery were randomly assigned to PTA
(n¼ 10) or PTAþEVBT (n¼ 10, 14 Gy by g-source). High-resolution MRI was performed prior, at 24-hours, 3-months,
and 24-months after intervention. MRI data were analyzed by an independent, blinded observer.
Results. The effects of both procedures on vessel wall at 24-hours and 3-months have been reported. Despite similar percent
decrease in lumen area between 3- and 24-months in both groups (8% for PTA and 11% for PTAþEVBT), at
24-months lumen area gain compared to baseline was þ30% in PTA versus þ82% in PTAþEVBT (p< 0.05). Total vessel
area, which was increased at 24-hours and 3-months, returned to pre-treatment value in both groups.
Conclusions. We demonstrated non-invasively that restenosis and inward remodeling after PTA are delayed by EVBT. At
24-months, patients treated with brachytherapy have larger lumen than those treated with PTA alone. The decrease in
luminal and total vessel area between 3- and 24-months after EVBT indicates that the restenotic and remodeling process
is not abolished but delayed with this therapy.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Percutaneous transluminal angioplasty (PTA) of se-
vere arterial stenosis has become the treatment of
choice in most vascular territories.1,2 The mechanisms
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lar brachytherapy; IVUS¼ intravascular ultrasound; TVA¼ total
vessel area; IL¼ interventional length; T1W¼ T1-weighted;
PDW¼ proton density-weighted; T2W¼ T2-weighted; TR¼ repeti-
tion time; TE¼ echo time; ANOVA¼ analysis of variance between
groups.
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cally explained with a displacement of atheroth-
rombotic plaque material into the vessel wall. We
recently documented in vivo that acute lumen en-
largement after PTA is mainly consequence of severe
disruption of atherothrombotic plaque, deep dissec-
tion into the vessel wall and positive (outward) vascu-
lar remodeling.3 The severity of the vascular injury
induced by balloon angioplasty and the following
negative (inward) remodeling of the arterial wall in-
duced by the vascular healing process could partially
explain the high restenosis rate after invasive proce-
dures. In fact, restenosis still remains the major limita-
tion of PTA in medium and small size vessels such as
femoropopliteal arteries, especially in the setting of
long lesions and poor vessel run-off.4 Several anti-
proliferative treatment strategies have been tested to
reduce restenosis. Among them endovascular bra-
chytherapy (EVBT) appears to be one of the mostlar Surgery. Published by Elsevier Ltd. All rights reserved.
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lated anti-restenotic properties of EVBT on vessel wall
remains mainly unclear. Until now, most of the hu-
man in vivo data on the assessment of the effects of
EVBT on vascular wall and lumen have been obtained
by intracoronary ultrasound (IVUS).7 This imaging
methodology has been extensively used to study pro-
gression of atherosclerosis and the process of resteno-
sis after PTA.8e10 However, the invasiveness of IVUS
represents a major limitation for sequential follow-up
examinations in humans.
Magnetic resonance imaging (MRI) allows serial,
noninvasive in vivo assessment of interventions on
atherothrombosis in several vascular beds such as
the aorta, the carotid and femoral arteries.11e16 In
vivo high resolution MR imaging has been validated
in human atherosclerotic femoral arteries with intra-
vascular ultrasound (IVUS). MRI showed high con-
cordance with IVUS for assessment of lumen area,
vessel wall dimensions and vascular calcifications.17
We recently reported the effects of PTA and PTAþ
EVBT at 24-hours and 3-months follow-up in the same
group of patients.3 PTA induced deep dissection into
the vessel wall. Interestingly enough, at 3 months pla-
que disruption and dissection were completely healed
in patients treated with balloon dilatation only,
whereas these features persisted in about 50% of the
patients treated with combined approach of balloon
dilatation and local endovascular brachytherapy.
Luminal loss after PTA was partially due to inward
vessel remodeling. Brachytherapy prevented inward
remodeling and induced an increase in lumen area
at 3 months, but partially prevented healing of the
disrupted vessel surface.
The aim of the present study was to compare the
long-term effects of PTA and PTAþEVBT on severely
stenotic femoropopliteal lesions by means of serial,
noninvasive high resolution MRI.
Patients and Methods
Each patient gave his or her written informed consent
to participate in the study, which was approved by the
local ethics committee.
Twenty consecutive symptomatic patients (71.4
6.5 years, 14 males) aged older than 55 years with
claudication (3 to the Rutherford scale) and severe
superficial femoropopliteal artery stenosis were in-
cluded in the study and randomly assigned to PTA
alone (n¼ 10) or PTAþEVBT (n¼ 10, 14 Gy by
gamma-source), and imaged by high-resolution MRI
before, 24-hours, 3-months and 2 years after interven-
tion (Fig. 1). Patients were not eligible for the study ifthey had non-atherosclerotic occlusive disease, vascu-
lar surgery during the preceding 6 months, uncon-
trolled hypertension, hemorrhagic diathesis, impaired
renal function (creatinine level >180 mmol/l), life ex-
pectancy of <2 years, or contraindication for MRI. All
patients underwent treatment with Aspirin 100 mg
daily and statins (atorvastatin 40 to 80 mg/day).
Percutaneous transluminal angioplasty
All interventional procedures were performed by
a standard (Seldinger) technique by using intra-arterial
digital subtraction angiography (Integris V 3000,
Philips Medical Systems, Best, The Netherlands). No
atherectomy device or stent implantation was allowed.
Ipsilateral anterograde puncture of the common
femoral artery and a 6F introducer sheath (Cordis
Europe NV) were used in all procedures. Five or six
millimeters balloon catheters were used to perform
angioplasty of the stenotic lesions. The segment at
which angioplasty was performed was marked with
a radio opaque ruler, and movement of the table and
angiographic unit was avoided in order to prevent
parallax error. One to one randomization was per-
formed by using sealed envelopes to assign patients to
PTA alone or PTAþEVBT at the end of the standard
PTA procedure.
Endovascular brachytherapy
Endovascular brachytherapy was performed by a sin-
gle radiotherapist (with 10 years of experience in
radiation therapy) at a high dose rate by using
gamma-irradiation by a 192Ir-source. A 5F closed-tip
non-centered applicator catheter (Nucletron) was
advanced through the 6F sheath and placed in the bal-
loon-treated lesion, so that the tip of catheter reached
1.5 cm distal to the distal end of the interventional
Intervention
24 hours MRI follow-up 
3 months MRI follow-up 
24 months MRI follow-up 
Reintervention n = 1 
Death n = 1 
Lost to follow-up Withdrew
consent n = 1
20 patients with claudication Rutherford  3
PTA
n = 10
PTA + EVBT 
n = 10 
n = 10 n = 10 
n = 10 n = 10 
n = 8 n = 9 
Fig. 1. Study flow chart.Eur J Vasc Endovasc Surg Vol 34, October 2007
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the IL plus 1 cm on the distal and proximal end. The
dose distribution was calculated by means of a com-
puter assisted planning system (Plato-BPS, version
13.2, Nucletron) with a 2.5 mm stopping point. The
reference dose of 14 Gy was applied in a depth of
5 mm from the source (reference vessel radius 3 mm
plus reference depth of 2 mm in the center of the
IL). Marks on a dummy wire measured the IL and
the length of the angioplasty segment. After its defini-
tion the dummy wire was removed. The application
catheter was connected to the after-loader and the
source was advanced into the applicator. No sham
procedure was performed in patients treated with
PTA only; therefore the patients and the interven-
tional radiologist were not blinded to the procedure.
In contrast, an investigator blinded to patient identity,
DSA findings and treatment group performed the off
center analysis of the MRI images.
Magnetic resonance imaging and analysis
Magnetic Resonance Imaging (MRI) consisted in serial
high resolution studies performed in all patients be-
fore PTA, 24-hours, 3 months and 24-months after
PTAEVBT using a 1.5-Tesla unit, (Gyroscan Intera,
Release 8.1; Philips Medical Systems, Best, The
Netherlands) with a gradient strength of 30 mT/m
and a slew rate of 150 mT/m/ms.
The current MRI protocol which has been previ-
ously described in detail [3] consisted of the following
3 steps: (1) Gradient echo scout series to localize ana-
tomical structures, (2) time-of-flight MR angiography
to localize the stenotic lesion and provide anatomic
landmarks in order to define precise location of the
stenosis of interest, and (3) plaque imaging sequences.
T1-weighted (T1W), proton density-weighted (PDW)
and T2-weighted (T2W) three dimensional, double in-
version recovery (black blood) fast spin echo se-
quences (2IR-FSE) with ECG-triggering were used to
obtain images in the axial plane. The 3D volume of
cross-sectional images was acquired perpendicular
to the long axis of the vessel of interest. Predefined
anatomical landmarks, for example the distance be-
tween common femoral artery bifurcation to maxi-
mum stenosis were used to obtain reproducible
image positions in the different studies (Fig. 2). All
subsequent plaque imaging sequences were then per-
formed by using this superficial receive-only coil cen-
tered at the level of the stenosis of interest.
High resolution MR images were acquired by using
the following parameters: repetition time (TR) 2 to 3 RR
intervals for T2W/ PDW and 1 RR for T1W; echo time
Eur J Vasc Endovasc Surg Vol 34, October 2007(TE): T2W 42 msec, PDW and T1W 9.4 msec; field of
view, 9 9 cm; slice thickness, 2,5 mm; acquisition ma-
trix, 256 218 (zero-filled interpolated to 512 436, in
order to reduce the partial-volume effects in imaging
pixels); in plain resolution, 0.35 0.41 mm; number
of slices, 10 for each for each sequence; 2 signal aver-
ages; scan mode, 3D; echo train-length 24; bandwidth
310 Hz per pixel; echo spacing 9.4 msec. The signal
from fat was reduced by a chemical shift suppression
pulse. The total MRI examination time was approxi-
mately 35 to 45 minutes.
Computer-assisted quantitative analysis of the MR
cross-sectional images (Image Pro-Plus, Media Cyber-
netics) was performed by a blinded operator (RC) us-
ing manual tracing of the vessel borders. Lumen area
was defined as the area encompassed by the inner
boundary of the intimal surface. Total vascular area
was defined by the outer vessel boundary, and vessel
wall area was calculated by subtracting lumen area
from the total vessel area (Fig. 2). Area measurements
were performed on PDW images. In cases with sub-
optimal image quality T1W images were used for
Fig. 2. MRI method for serial plaque imaging: after localiza-
tion of the stenosis of interest, a 3D volume (yellow box),
containing 10 contiguous cross-sectional images perpendic-
ular to the lumen axis was acquired and matched over time
using measurements from anatomical landmarks (such as
common femoral artery bifurcation). Manual tracing of ves-
sel border (lumen and outer border) was performed to
quantify vessel dimensions (lower panel). Outer vessel bor-
der defined the total vessel area (TVA). V: Femoral vein.
419Vascular Remodeling after Femoral PTA by MRIanalysis. Quantitative changes in cross sectional MR
images were compared to pre-PTA values. The mean
value of 10 contiguous MR images centered in the le-
sion was computed for statistical analysis. Matching
of the MR images was performed using vascular land-
marks. The presence of vessel wall disruption was
evaluated visually in all lesions. Dissection after PTA
was defined as the presence of a tear in the intimal sur-
face separating the lesion from the underlying arterial
wall.
Statistics
Data are presented as mean 1SE. Percent changes
are reported as 100(mean at time T2 mean at time
T1)/(mean at time T1). Statistical analysis was per-
formed using ANOVA for repeated measures (Stat
View 4.1, ABACUS Inc) and student t test. A value
of P< 0.05 was considered significant.
Results
Baseline clinical data, angiographic and procedural
characteristics from patients are shown in Tables 1
and 2. The two groups (i.e., PTA and PTAþEVBT),
Table 1. Baseline clinical characteristics of patients according to
assigned treatment
PTA Group
(N¼ 10)
PTAþEVBT
(N¼ 10)
Males 7 7
Females 3 3
Age (y) 73.4 6.6 68.7 6.1
History of smoking 7 5
Arterial hypertension 6 6
Cholesterol, mmol/l 5.8 1.4 5.5 1.0
Triglycerides, mg/dL 2.6 0.7 2.1 1.0
CAD (angina pectoris and/or prior
myocardial infarction
5 5
Diabetes 6 4
Duration of symptoms, (mo) 5.9 5.0 6.3 5.5
Clinical stage
Serum Creatinine level, mmol/l 106 26 103 19
Rest pain and/or tissue damage 1 0
Rutherford stage 3/4 7/3 9/1
Medication
Aspirin 10 10
Statin (atorvastatin
40 to 80 mg/day)
10 10
Calcium antagonist 2 1
Angiotensin-converting enzyme
inhibitor
4 2
ATII-antagonist 1 3
B-blocking 3 5
Antidiabetics 5 4
10 patients were included per group. Deviations are reported
as 1 standard deviation.consisting of 10 patients each, had comparable baseline
characteristics, including risk factors for occlusive vas-
cular disease and lesion characteristics. All patients
had immediate angiographic success, which had been
defined as less than 50% residual stenosis in the treated
segment, and there were no complications related to
PTA. There were no procedural or radiation-related
complications, such as thromboembolic occlusion of
a peripheral vessel or acute occlusion within the irra-
diated region on control angiography performed
immediately after EVBT. There was no case of late
thrombotic occlusion in the EVBT group or formation
of aneurysms.
Two-years follow-up was not available in one
case in the EVBT group because the patient refused
to undergo the MRI follow-up examination. Two
patients of the PTA only group were lost to 2-years
follow-up examination due to the need of reinterven-
tion because of restenosis or death unrelated to
cardiovascular disease (Fig. 1).
Table 2. Angiographic and procedural characteristics at baseline
PTA
(N¼ 10)
PTAþEVBT
(N¼ 10)
Target vessel
Superficial femoral artery 5 8
Popliteal artery 5 2
De novo lesions 10 10
Morphology
Centric 8 10
Eccentric 2 0
Mean lesion length (cm) 2.8 1.7 2.0 1.7
Occlusion 0 0
Stenosis 10 10
Stenosis/occlusion length
 2 (cm) 5 7
2.1e5.0 (cm) 5 2
5.1e8.0 0 1
Balloon dilation
Balloon length (cm) 4.8 2.9 4.0 1.6
Balloon diameter (mm) 4.8 0.8 5.5 1.0
Runoff vessels
No or 1 patent artery 2 3
2 or 3 patent arteries 8 7
Irradiation procedure
Treated length (cm) e 9.2 3.4
Prescription point (distance from
vessel center) (mm)
e 4.8 0.5
Source strength (Gy/hm2) e 2.7 0.9
Irradiation duration (sec) e 17.0 6.1
Dose min. (Gy) e 10.4 0.2
Dose max. (Gy) e 14.9 0.2
Dose rate min at prescription point
(Gy/min)
e 41.4 16.3
Dose rate max at prescription point
(Gy/min)
e 59.4 22.9
Unless otherwise specified, data are reported as number of patients;
continuous data are reported as means 1 standard deviation.Eur J Vasc Endovasc Surg Vol 34, October 2007
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Cross-sectional MRI before intervention revealed an
average percent area stenosis of 80% (ranging 69 to
92%), which did not differ between the treatment
groups. Short and mid term results of PTA and
EVBT have been previously reported 3. In summary,
cross-sectional MR imaging performed at 24-hours af-
ter percutaneous intervention revealed deep disrup-
tion of the atherosclerotic plaques and no difference
in lumen area, total vessel area and vessel wall area
between the groups. At 3 months luminal loss after
PTA was partially due to inward vessel remodeling.
Brachytherapy prevented inward remodeling and
induced an increase in lumen area, but partially pre-
venting healing of disrupted vessel surface (Fig. 3).
Quantitative data are included in Table 3.
Chronic effects on lumen area
At 24 months, patients treated with PTAþEVBT main-
tained a significantly larger lumen area compared to
those treated with PTA alone ( p¼ 0.047, between groups
over time comparison, Table 3. Compared to baseline,
cross-sectional lumen area increased at 24-months
follow-up by 30% in the PTA and by 82% in the PTAþEVBT group, despite similar results immediately
after the intervention. Interestingly, a trend towards
restenosis was observed at 24 months in the PTAþ
EVBT group with a non-significant lumen loss of 11%
compared to the 3-months follow-up ( p¼ 0.056). The
quantitative analysis reported in Fig. 4 demonstrates
that EVBT delayed the restenotic and remodeling pro-
cess as indicated by the shifting of the curves to the
right.
Chronic effects on total vessel area
Between 3 and 24 months follow-up MRI revealed
a significant reduction in TVA in both groups, which
at 24 months did not differ anymore between the
groups ( p¼ 0.08, between groups over time compari-
son) indicating that inward remodeling occurred also
in the PTAþEVBT group.
Deep dissection and disruption of the atheroscle-
rotic plaque were seen acutely after intervention but
were no longer visible in the PTA group at 3-months
follow-up, indicating healing of the vessel wall. On
the contrary, dissection or splitting of the atheroscle-
rotic lesion persisted in 50% and in 10% of the patients
treated with PTAþEVBT after 3 and 24 months,
respectively.Fig. 3. Representative MR cross-sectional images in patients treated with PTA alone (upper panel) and with PTAþEVBT
(lower panel) before, at 24 hours, 3 and 24 months after intervention. Zoomed cross-sectional images at the level of the
artery are included in the panel in the left corner (4 time enlargement for PTA and 3 time enlargement for PTAþEVBT images).
Acutely, similar enlargement of lumen area and expansion of vessel wall (outward remodeling) was seen in both groups.
Patients treated with PTA alone showed features of inward remodeling already at 3 months, which was delayed in those
treated with PTAþEVBT.
Eur J Vasc Endovasc Surg Vol 34, October 2007
421Vascular Remodeling after Femoral PTA by MRITable 3. Quantitative data of cross-sectional vessel dimensions by serial MRI
Baseline 24 hrs 3 mo 24 mo P* Py
PTA vs.
PTAþEVBT
Lumen PTA 11.9 3 22.2 3.5 16.7 3 15.4 3 0.017 0.047
PTAþEVBT 12.4 3 20.7 3 25.5 5 22.7 3 0.0015
TVA PTA 57.1 10 84.0 11.5 65.4 11 53.0 9 0.0044 0.08
PTAþEVBT 55.7 10 74.7 10 77.5 16 63.0 5 0.0041
VWA PTA 45.2 7 61.8 8 48.7 8 37.6 7 0.009 0.3
PTAþEVBT 43.2 7 54.0 8 52.1 11 40.3 8 0.017
TVA: total vessel area, VWA: vessel wall area. hrs: hours, mo: months.
Values are given in mm2.
* ANOVA for repeated measures.
y ANOVA for repeated measures treatment.Discussion
We demonstrated non-invasively using serial MRI that
restenosis and inward remodeling after PTA are de-
layed by EVBT. Percutaneous balloon intervention
led to a significant enlargement of the lumen area
that was maintained up to 2 years. The combination
of balloon angioplasty and brachytherapy led to an
even more pronounced enlargement of the lumen
area. Patients treated with PTA alone showed no fur-
ther decrease in lumen area between 3 and 24-months
Fig. 4. Line graphs showing the effect of PTA (white) and
PTAþEVBT (black) on lumen area (P¼ 0.047 between
groups over time) and total vessel area (P¼ 0.08 between
groups over time). BL: Baseline; 24 hrs: at twenty-four
hours; mo: months. Square: lumen area. Circle: total vessel
area (TVA).follow-up, whereas luminal loss was observed in those
treated with brachytherapy. Therefore, EVBT does not
abolish but appears to delay significantly the process of
restenosis. Similarly, the negative (inward) remodeling
of the vessel wall, as shown by the decrease of the total
vessel area, was also retarded in the brachytherapy
group compared to the PTA group.
We conclude that EVBT initially prevents restenosis
and even enhances the outward (positive) remodeling
of the vessel wall within the first three months after
PTA but the process of restenosis appears to begin be-
fore 24 months. These findings are in agreement with
a recently published study from Wolfram and col-
leagues who demonstrated that the applied dose of
12 Gy gamma irradiation inhibited recurrence of dis-
ease at 6 months follow-up when compared with
PTA alone. Between 36 and 60 months they observed
a late catch-up phenomenon and comparable stenosis
recurrence rate at 5 years follow-up.18 Another recent
publication confirms the lack of a sustained angio-
graphic, hemodynamic and clinical benefit of EVBT
after a mean follow-up of 32 months.19 In addition
to these two studies that used digital subtraction angi-
ography for follow-up after vascular intervention, our
MRI data also allowed not only measurement of lu-
men area but also assessment of vascular remodeling
after endovascular therapy which is known to play
a major role in restenosis after PTA.
The current study demonstrates the potential of
MRI for serial assessment of vascular remodeling
which is a major factor in restenosis after angio-
plasty.20,21 At present, IVUS is considered the gold
standard for quantitative evaluation of arterial remod-
eling in humans. However, in contrast to MRI serial
application of IVUS in humans is limited because of
its invasiveness.
Our study shows that even though lumen area is
significantly increased by EVBT at three and 24
months this happens at the expense of the delayed
healing of the balloon-induced deep disruptions of
Eur J Vasc Endovasc Surg Vol 34, October 2007
422 R. Wyttenbach et al.the vessel wall. This should draw the attention to the
community of interventionalists to limit this treat-
ment modality to selected patients. In fact, the persis-
tence of dissections and delayed healing with the
associated changes in the biological properties of the
intima and in particular of the endothelium may
eventually even lead to increased thrombogenic fea-
tures in these vessels such as observed in patients
treated with EVBT and stent implantation after dis-
continuing double antiaggregant therapy (Aspirin
and Clopidogrel).22e24
A potential limitation of the present study is the
small number of patients included. However, high
resolution MRI has been validated in several experi-
mental studies with histology and IVUS for assess-
ment of atherosclerosis of the vessel wall.25e27 High
resolution MRI measures cross-sectional lumen area,
which is known to correlate better with hemodynamic
effect of stenosis than does a reduction in diametric
measurements as provided by catheter-based angiog-
raphy.28 In addition, the study design with serial imag-
ing allowed each patient to act as his own control and
therefore limits the number of needed observations.
In conclusion, high-resolution MR imaging after
PTA shows deep disruption of the atherosclerotic pla-
ques followed by extensive remodeling process of the
arterial wall. Luminal loss after PTA is partially due to
inward vessel remodeling. Brachytherapy initially
prevents inward remodeling and induces an increase
in lumen area, at a cost of persistent plaque disruption
in some patients. The remodeling and healing process
appear to be delayed by endovascular brachytherapy
compared to PTA alone but begins before 24 months.
Our results support the hypothesis that restenosis
may be delayed in patients treated with EVBT at the
price of persistent dissection with the potential risk
of late thrombosis.
The current study also confirms that MRI can be
used to assess in vivo the long term effects of inter-
ventions (such as PTA and EVBT) on femoral artery
as has been the case for studies investigating the
effect of lipid-altering drugs on carotid artery and
aorta.
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